Glenmark Pharma gets USFDA nod for Aprepitant Capsules

Glenmark Pharma gets USFDA nod for Aprepitant Capsules

62
Glenmark logo

 

Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Aprepitant Capsules USP, 40 mg, 80 mg, and 125 mg, the generic version of Emend Capsules, 40 mg, 80 mg, and 125 mg, of Merck Sharp & Dohme Corporation.

Glenmark’s current portfolio consists of 127 products authorized for distribution in the U.S. market place and 60 ANDA’s pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

All brand names and trademarks are the property of their respective owners.